European Union Concerted Action on the Molecular Biology of Immunosenescence
EUCAMBIS is a Biomed I concerted action, running from 1st June 1994 to 31st Dec 1997:
Supported by the EC through contract number BMHI CT94 1209.
The continuation programme, ImAginE - Immunology and Ageing in Europe - started on 1st February 2000.
Concerted actions provide support to build networks of European researchers interested in collaborating across national borders on projects of common interest. CAs are conceived of as furthering contact by supporting meetings, workshops, individual visits and personnel, data and materials exchanges. EU funding is provided only to further interactions, not for the research work itself.
Original objectives of the project
- To investigate the molecular genetic basis and functional correlates for immunosenescence of human T-lymphocytes.
- To resolve the controversy of whether immunosenescence is partially or wholely caused by the active upregulation of new genetic programmes involving the participation of any or all of "senescence-inducing (SI)", "growth arrest-specific (GAS)" and "tumour-suppressor (TS)" genes, and the relationship of these to cell cycle control genes.
- To manipulate gene expression in cultured cells and in ex vivo material in order to establish a model for modifying processes resulting in immunosenescence in vivo.